Menu

ISTOCK, VOGELSP

Seven Researchers Guilty of Misconduct in Macchiarini Case

The Karolinska Institute’s latest decision includes a guilty verdict for one of the whistleblowers who contributed to the investigation.

Jun 25, 2018
Catherine Offord

Italian thoracic surgeon Paolo Macchiarini and six of his colleagues, one of whom was a whistleblower, have been found guilty of scientific misconduct in the latest investigation into the infamous researcher’s work by his former institution, the Karolinska Institute in Sweden. In a statement published yesterday (June 25), the Institute announced that an analysis of six articles published across four journals had discovered inaccuracies, misleading information, data fabrication, unjustified treatments, and a lack of appropriate ethical approvals. An additional 31 authors were deemed “blameworthy” for their contributions to the publications.

“This decision has been made after careful investigations in a case that has had major impact on Karolinska Institutet, on the scientific community at large, and on public confidence in medical research,” the Karolinska Institute’s president, Ole Petter Ottersen, says in the statement. “In particular, the case has had tragic consequences for patients and their relatives, for which I am deeply sorry. Karolinska Institutet will now continue to implement the measures that are necessary to prevent something like this from happening again.”

See “Girl with Synthetic Trachea Dies

Macchiarini’s research centered on a radical approach to tracheal transplantation that involved seeding bioengineered windpipes with a patient’s own stem cells. His work became the subject of multiple investigations following the deaths of several patients, along with allegations of ethical oversights and data fabrication. 

See “Karolinska Finds Macchiarini Guilty of Misconduct

Macchiarini himself was found guilty of scientific misconduct by the Karolinska Institute (KI) at the end of 2016, along with three coauthors, following an investigation relating to a paper published in Nature Communications in 2014. That paper was retracted in March, 2017. The latest announcement by the institution requests the retraction of all six articles examined in the investigation, all of which were published between 2011 and 2014, mirroring recommendations made by Sweden’s Central Ethics Review Board after its own investigation in 2017. 

See “Swedish Ethics Review Board: Macchiarini is Guilty

A spokesperson for The Lancet, where two of the papers were published, tells Retraction Watch, “We welcome the report from the Karolinska Institute. We will study their findings and conclusions carefully and respond as soon as possible.”

Regarding the decision to find one of the four whistleblowers guilty of misconduct, Ottersen notes that “it is KI’s firm opinion that a whistle blower who has participated in a scientific study and also as author of a scientific article, despite reporting, cannot be freed from blame or absolved from responsibility.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.